Viking Therapeutics, Inc. (VKTX)

NCM – Real Time Price. Currency in USD

31.32

-0.40 (-1.26%)

At close: May 12, 2026, 4:00 PM EDT

12.05.2026

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau Dose-dependent weight loss observed across all VK2735 cohorts, with the highest dose achieving a mean reduction of up to 12.2% (26.6 lbs) from baseline at Week 13 Baseline characteristics in the ongoing Phase 3 VANQUISH-1 study of VK2735 in adults with obesity were also presented in a second poster at the conference SAN DIEGO, May 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today presented additional data from its Phase 2 VENTURE-Oral Dosing trial evaluating the oral tablet formulation of VK2735 at the European Congress on Obesity (ECO) in Istanbul, Türkiye. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development with subcutaneous and oral formulations for the potential treatment of various metabolic disorders.

05.05.2026

Viking Therapeutics: Market Betting On Big Upside Through 2030

Viking Therapeutics is making really solid pipeline progress and possesses a unique dual agonist approach in the fast-growing obesity drugs market. VKTX targets a 5–10% market share, leveraging global expansion and late-stage development to compete with incumbents Lilly and Novo Nordisk. Nothing is over just yet. Phase 3 for VK2735 Oral is set for late 2026, with initial commercial ramp expected in 2028 and potential $1.3B sales by 2030. A hockey stick inflection could pan out.

05.05.2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735 SAN DIEGO, May 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that it will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) taking place in Istanbul, Türkiye on May 12-15, 2026. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viking is developing in subcutaneous and oral formulations for the potential treatment of various metabolic disorders, including obesity.

01.05.2026

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge

Buy the story, sell the news. That's a reasonable explanation for why Viking Therapeutics NASDAQ: VKTX fell over 3% the day the company delivered its Q1 2026 earnings report.

30.04.2026

VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

Viking Therapeutics posts a wider Q1 loss as R&D spend jumps on Phase III obesity drug work, while it advances VK2735 studies and preps oral late-stage study.

30.04.2026

Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard

Viking Therapeutics, Inc. remains a hold as competitive pressure mounts in the GLP-1 obesity/diabetes space, with its lead VK2735 candidate lagging larger peers. VKTX's Phase 3 VANQUISH studies are fully enrolled, but pivotal data are not expected (by me) until late 2027/early 2028, making near-term catalysts limited. The upcoming Q3 maintenance study readout is a potential wildcard; positive results could enable VKTX to raise additional capital and regain momentum.

30.04.2026

Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript

Videos

No Data

There is no data to display

Press releases

12.05.2026

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

05.05.2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

29.04.2026

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled -- -- Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26 -- -- VK2735 Maintenance Dosing Study Ongoing; Data Expected 3Q26 -- -- IND Filed for Novel Amylin Agonist VK3019; Phase 1 Trial Initiation Expected 2Q26 -- -- Strong Quarter-End Cash Position of $603 Million -- SAN DIEGO, April 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline and other corporate developments.

26.03.2026

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.

Viking Therapeutics, Inc. (VKTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Viking Therapeutics: Market Betting On Big Upside Through 2030

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge

VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard

Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Viking Therapeutics: Market Betting On Big Upside Through 2030

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge

VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard

Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Search stocks

Viking Therapeutics, Inc. (VKTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Viking Therapeutics: Market Betting On Big Upside Through 2030

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge

VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard

Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Viking Therapeutics: Market Betting On Big Upside Through 2030

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge

VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard

Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735